143 related articles for article (PubMed ID: 7199467)
1. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467
[No Abstract] [Full Text] [Related]
2. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
Stewart DJ; Leavens M; Friedman J; Benjamin RS; Moore EC; Bodey GP; Valdivieso M; Burgess MA; Wiseman C; Loo TL
Cancer Res; 1980 Sep; 40(9):3163-6. PubMed ID: 7427934
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
4. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
[No Abstract] [Full Text] [Related]
5. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
[TBL] [Abstract][Full Text] [Related]
6. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
Erlichman C; Strong JM; Chabner BA
Cancer Res; 1980 Jun; 40(6):1902-6. PubMed ID: 7371023
[TBL] [Abstract][Full Text] [Related]
7. Cooperative binding of the bisubstrate analog N-(phosphonacetyl)-L-aspartate to aspartate transcarbamoylase and the heterotropic effects of ATP and CTP.
Newell JO; Markby DW; Schachman HK
J Biol Chem; 1989 Feb; 264(5):2476-81. PubMed ID: 2644262
[TBL] [Abstract][Full Text] [Related]
8. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis.
White JC; Hines LH
Cancer Res; 1984 Feb; 44(2):507-13. PubMed ID: 6692357
[TBL] [Abstract][Full Text] [Related]
9. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
[TBL] [Abstract][Full Text] [Related]
10. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
[TBL] [Abstract][Full Text] [Related]
11. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
12. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
[TBL] [Abstract][Full Text] [Related]
13. The binding of N-(phosphonacetyl)-L-aspartate to aspartate carbamoyltransferase of Escherichia coli.
Volź KW; Krause KL; Lipscomb WN
Biochem Biophys Res Commun; 1986 Apr; 136(2):822-6. PubMed ID: 3518720
[TBL] [Abstract][Full Text] [Related]
14. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
White JC; Hines LH
Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
[TBL] [Abstract][Full Text] [Related]
17. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Chan TC; Markman M; Cleary S; Howell SB
Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of the interaction of N-(phosphonacetyl)-L-aspartate with the catalytic subunit of aspartate transcarbamoylase. A slow conformational change subsequent to binding.
Cohen RE; Schachman HK
J Biol Chem; 1986 Feb; 261(6):2623-31. PubMed ID: 3949739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
